About ARTBIO
ARTBIO is a Healthcare company based in Sacramento (United States) founded in 2021 by Roy H Larsen and Oyvind Bruland. Alpha radioligand therapies for cancer are developed using lead-212. ARTBIO has raised $245.3 million across 3 funding rounds from investors including ARE, Third Rock Ventures and F-Prime Capital. Its chief executive, as recorded, is Emanuele Ostuni. ARTBIO offers products and services including AB001, AlphaDirect TM, and Pipeline Programs. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ARTBIO Inc. Its competitors include SOFIE, Mariana Oncology and Lantheus; 2 of its 3 listed competitors have raised funding.
Company details
ARTBIO was founded in 2021 and is based in Sacramento, United States. Alpha radioligand therapies for cancer treatment are developed by the company, with lead-212 employed as the primary alpha-emitting isotope. Operations focus on targeted radioligand applications in oncology. The lead program, AB001, is directed toward prostate cancer. Co-founders include Roy H. Larsen and Oyvind Bruland, with Emanuele Ostuni serving as CEO.
- Headquarters Sacramento, United States
- Founders Roy H Larsen, Oyvind Bruland
- SectorsHealthcare
- Email••••••••
- Website artbio.com
- Social LinkedIn X
- Legal Name Artbio Inc.
- Total Equity Funding$245.3M (USD)
in 3 rounds
- Latest Funding Round$132M (USD), Series B
Jul 2025
- InvestorsARE
& 6 more
Products & Services of ARTBIO
ARTBIO offers a comprehensive portfolio of products and services, including AB001, AlphaDirect TM, and Pipeline Programs.
Targets prostate cancer with precise radiation treatment
Produces isotopes for advanced cancer therapies
Develops multiple therapies for various solid tumors
Funding Insights of ARTBIO
ARTBIO has successfully raised a total of $245.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $132 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $245.3M
- Total Rounds 3
- Last Round Series B — $132M
- First Round $23.3M
(Jun 2023)
- Investors Count 7
All 3 funding rounds of ARTBIO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $132M | Series B | – | Sofinnova Investments, B Capital | |
| Dec 2023 | $90M | Series A | – | Third Rock Ventures | |
| Jun 2023 | $23.3M | Seed | – | F-Prime Capital, Omega Funds | – |
7 investors in total: 7 institutional.
Investors in ARTBIO
ARTBIO has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Third Rock Ventures and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital firm | omegafunds.com | Boston, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Multistage investments are directed toward technology, healthcare, and climate sectors. | b.capital | Manhattan Beach, United States | ||
A sovereign wealth fund backed by Qatar, managing investments and funds. | 2005 | qia.qa | Doha, Qatar | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for ARTBIO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ARTBIO
15 people are tracked at ARTBIO (11 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Roy H Larsen | Co-Founder | Leadership |
Oyvind Bruland | Co-Founder | Leadership |
Emanuele Ostuni | CEO | Leadership |
Philippe Dasse | Chief Technical Officer | Leadership |
Nick Pullen | Chief Scientific Officer | Leadership |
Bharat Lagu | Senior Vice President, Discovery | Leadership |
Victor Paulus | Head And Senior Vice President, Regulatory Affairs | Leadership |
Jordi Vall-Llossera | Senior Vice President And Global Head Of Quality | Leadership |
Calvin J. Lee | Finance Director | Leadership |
Dilovan Cati | Senior Director, Analytical Science And Technology Lead | Leadership |
Heng Li | Director Of Early Discovery | Leadership |
Phil Ruis | Portfolio And Business Development | Team |
Christina Hiemeyer | Senior Research Associate | Team |
Susanne Schaffert | Independent | Team |
Angela M. Zaino | Scientist II | Team |
Complete people profiles for ARTBIO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ARTBIO
3 dated milestones of ARTBIO across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ARTBIO is founded.
- Funding First funding round of $23.3M.
- Funding Latest funding round, Series B, of $132.0M.
Competitors of ARTBIO
ARTBIO has 3 listed competitors in our database, 2 of them funded. They include SOFIE, Mariana Oncology and Lantheus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| marianaoncology.com | 2020 | Watertown, United States | $250M | 41 | Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | |
| lantheus.com | 2008 | Billerica, United States | 834 | Developer of diagnostic imaging agents and targeted therapeutics |
Detailed competitors of ARTBIO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ARTBIO
The website of ARTBIO (artbio.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▼ 36.4% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as ARTBIO (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Artbio
Complete news archive for ARTBIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ARTBIO
ARTBIO was founded in 2021 and raised its 1st funding round 2 years after it was founded.
ARTBIO is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Emanuele Ostuni is the CEO of ARTBIO, as recorded in our data.
ARTBIO is a funded company, having raised a total of $245.3M across 3 funding rounds to date. The company's 1st funding round was a Seed of $23.3M, raised on Jun 2023.
ARTBIO was founded in 2021 and is based in Sacramento, United States. Alpha radioligand therapies for cancer treatment are developed by the company, with lead-212 employed as the primary alpha-emitting isotope. Operations focus on targeted radioligand applications in oncology. The lead program, AB001, is directed toward prostate cancer. Co-founders include Roy H. Larsen and Oyvind Bruland, with Emanuele Ostuni serving as CEO.
ARTBIO's top competitors include SOFIE, Mariana Oncology and Lantheus.
ARTBIO offers AB001, AlphaDirect TM, and Pipeline Programs.
ARTBIO has 7 investors. Key investors include ARE, Third Rock Ventures, F-Prime Capital, Omega Funds, and Sofinnova.
ARTBIO operates through Artbio Inc..